Zurich – Smart Blood Analytics Swiss (SBAS) receives EU certification for its VIRUS vs BACTERIA model. It helps to differentiate between viral and bacterial infections and thus supports doctors in targeted treatment.
The Zurich-based company Smart Blood Analytics Swiss (SBAS) receives EU MDR (European Medical Device Regulation) certification for its VIRUS vs BACTERIA Clinical Decision Support Software. SBAS has thus taken a significant step towards the prevention of antimicrobial resistance, according to a press release. The innovative medical device sets new standards in the precise differentiation between viral and bacterial infections and thus supports doctors in the targeted and effective treatment of patients.
As the first clinical decision support software to receive EU MDR certification in the field of infectious disease management, VIRUS vs. BACTERIA uses only 17 routine blood parameters, biological sex and age to distinguish between viral and bacterial infections.
As routine blood tests are readily available worldwide, VIRUS vs. BACTERIA expands the physician's ability to differentiate between viral and bacterial infections, supporting the rational use of antibiotics, especially in the area where other commonly used blood markers offer limited diagnostic value.
According to the press release, antimicrobial resistance (AMR) poses a significant threat to global public health and contributes to millions of deaths every year. AMR undermines the effectiveness of treatments for infectious diseases, jeopardizes medical progress and significantly increases healthcare costs, particularly through the misuse and overuse of antibiotics. ce/gba